About Biopta
Biopta is a company based in Godalming (United Kingdom) founded in 2002 was acquired by ReproCELL in November 2015. Biopta has raised $1.57 million across 3 funding rounds from investors including Scottish Enterprise, ReproCELL and Braveheart Investment Group. Biopta operates in a competitive market with competitors including Anabios, Clyde Biosciences, Metrion Biosciences, Quiver Bioscience and Zen-Bio, among others.
- Headquarter Godalming, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.57 M (USD)
in 3 rounds
-
Latest Funding Round
$425.8 K (USD), Seed
Nov 04, 2010
-
Investors
Scottish Enterprise
& 3 more
-
Employee Count
Not available
-
Acquired by
ReproCELL
(Nov 25, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Biopta
Biopta has successfully raised a total of $1.57M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $425.8 thousand completed in November 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biopta
Biopta has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Scottish Enterprise, ReproCELL and Braveheart Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm
|
Locked | Locked | Locked | |
|
Early-stage Scottish companies are supported with investment and expertise.
|
Locked | Locked | Locked | |
|
Business development and leadership training programs are offered to companies.
|
Locked | Locked | Locked |
Investor details for Biopta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biopta
Investment portfolio details for Biopta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biopta
Detailed financials for Biopta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biopta Comparisons
Peer comparison for Biopta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biopta
Biopta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Anabios, Clyde Biosciences, Metrion Biosciences, Quiver Bioscience and Zen-Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ex-vivo human tissue studies are performed for preclinical drug discovery.
|
|
| Locked | Locked | Locked |
Cardiac safety testing is conducted using iPS-derived heart cells.
|
|
| Locked | Locked | Locked |
Ion channel screening and cardiac safety profiling services are provided.
|
|
| Locked | Locked | Locked |
Developer of transformational medicines for neurological disorders
|
|
| Locked | Locked | Locked |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
|
| Locked | Locked | Locked |
Multiplexed immunoassays for protein biomarkers are developed via proprietary platform.
|
Detailed competitors of Biopta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biopta
Complete news archive for Biopta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biopta
Biopta was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Biopta is headquartered in Godalming, United Kingdom.
Biopta is a funded company, having raised a total of $1.57M across 3 funding rounds to date.
Biopta Ltd is a contract research company focussed on the use of fresh functional human tissues in drug development. Biopta was spun out of Glasgow Caledonian University by its co-founders, Dr David Bunton and Professor Chris Hillier, with the aim of addressing the high failure rate of drugs during clinical trials through the use of ethically-sourced human tissues. Bioptas expertise in all areas of human tissue research including sourcing, handling and experimenting on human tissue. Biopta is able to provide early indications of drug safety, efficacy and absorption. Our human ex vivo pharmacology models bridge the gap between animal in vivo data and the clinic. In Nov 2015, the company was acquired by ReproCELL.
Biopta's top competitors include Metrion Biosciences, Quiver Bioscience and Anabios.
Biopta has 4 investors. Key investors include Scottish Enterprise, ReproCELL, Braveheart Investment Group, and TRICAPITAL Angels.